Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Day Light Reduces Price In Bid To Sell Off Pharmaceutical Subsidiaries

This article was originally published in PharmAsia News

Executive Summary

Due to the failure to secure a sales license in China, allegedly due to "tarnished" operations, U.S. direct sales firm Day Light has pulled out from the market. Its attempt three months ago to sell off two China subsidiaries, Day Light Pharmaceuticals and Day Light Biotechnologies, found no buyers, leading to the recent drop in offer price to about RMB 20 million. Sources reveal that the two subsidiaries' net asset was over RMB 40 million in 2006, and the current worth is estimated to exceed RMB 50 million. Day Light has suspended its China business since last October but to date has not refunded franchisees their fees. Lawyers representing the latter confirmed that the firm has yet to give a clear explanation. href='http://www.chinasecurities.com.cn/cqzk/11/200810/t20081010_1617756.htm'>(Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066853

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel